IKT · CIK 0001750149 · FY2025 live · 2025-12-31
Inhibikase Therapeutics, Inc.
View as
Model
Classic Z
FY2025
11.59
Zone
Safe
Prior
—
Market DD
—
1y PD
—
11.59
Z″ 23.60
Score 11.59 · distress below 1.80, grey to 2.99, safe at 3.00 and above.
Classic Z factor contributions
X1 Working capital / assets
Short-term liquidity versus the size of the balance sheet.
0.951.2 × = 1.14X2 Retained earnings / assets
Cushion from years of profits. Share buybacks can push this negative at otherwise healthy firms.
−0.791.4 × = −1.10X3 EBIT / assets
Operating return on assets. Highest weight in the original model.
−0.293.3 × = −0.95X4 Book equity / liabilities
Book equity versus the liability stack. Mega-caps often look greyer here than they would if X4 used market cap.
20.830.6 × = 12.50X5 Sales / assets
Asset turnover — how much revenue the asset base supports.
0.001 × = 0.00
Five-year path
Need two annual 10-Ks to draw a path. The desk will pull this issuer’s filings rather than invent a series.
Overview
rule-v1
Inhibikase Therapeutics, Inc. is on classic Z at 11.59 (safe) for FY2025, from an SEC 10-K. Book equity / liabilities is the line that sets the print. This is the first live year on the desk. No market tape loaded. Classic Z was fit on manufacturers; buybacks can send retained earnings negative at otherwise healthy issuers, and X4 is book equity, not market cap.
Book screen Safe; market PD —. Tape not priced — not a single default call.
Market DD · naive Merton
No market tape yet.
Pull a year of closes (Yahoo, Nasdaq if Yahoo is limited) and size equity from Nasdaq cap or EDGAR shares. Distance-to-default and 1-year PD stay blank until then.
Sector peers
Closest Classic Z scores · 97th percentile in Healthcare.
KPI widgets
Current assets
$180M
Total assets
$181M
Current liabilities
$8M
Total liabilities
$8M
Working capital
$172M
Retained earnings
−$143M
EBIT
−$52M
Total sales
$0
Book equity
$173M
Accession 0001193125-26-126371. Live rank is the latest 10-K on EDGAR (FY2025, period 2025-12-31). Classic Z is the live score. View as does not rewrite the live rank. X4 is book equity. Pulled 12 Sept 2026.